Published on 3 Apr 2024 on Benzinga
Ocugen Inc OCGN shares are trading higher by 14% to $1.58 during Wednesday’s session. The company yesterday provided an update on its business activities and financial status for the year ending 2023.
Ocugen highlighted progress in its modifier gene therapy programs for blindness diseases. Key developments include promising results in the OCU400 Phase 1/2 study for Retinitis Pigmentosa (RP), with FDA recognition through RMAT designation, potentially accelerating therapy delivery.